|Mr. David Loew||MD, CEO & Director||2.3M||N/A||1967|
|Mr. Aymeric Le Chatelier||Exec. VP & Group CFO||N/A||N/A||1969|
|Dr. Aidan Murphy Ph.D.||Exec. VP of Technical Operations||N/A||N/A||1966|
|Mr. Craig Marks||Vice-Pres of Investor Relations||N/A||N/A||N/A|
|Mr. Francois Garnier||Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer||N/A||N/A||1962|
|Ms. Gwenan White||Exec. VP of Communications & Public Affairs||N/A||N/A||N/A|
|Mr. Regis Mulot||Exec. VP & Chief HR Officer||N/A||N/A||1966|
|Mr. Stephan Gagne||Head of New Tokyo Office||N/A||N/A||N/A|
|Ms. Dominique Bery||Head of Nordics & Baltics||N/A||N/A||1971|
|Dr. Yan Moore M.D.||Sr. VP & Head of Oncology Therapeutic Area||N/A||N/A||1967|
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Ipsen S.A.’s ISS governance QualityScore as of 1 February 2023 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 7; Compensation: 7.